← Shelf·Angiotensin IV analog (hexapeptide)·XXXI.
Dihexa.
A hexapeptide (N-hexanoic-Tyr-Ile-(6) amino hexanoic amide) engineered as an orally-bioavailable analog of the angiotensin IV fragment 3-8. Developed by Joseph Harding and colleagues at Washington State University as a research tool for the hepatocyte growth factor / c-Met pathway in cognitive-decline models.
Angiotensin IV is a native fragment produced from angiotensin II by aminopeptidase cleavage; it binds the AT4 receptor, later identified as insulin-regulated aminopeptidase (IRAP). Dihexa is a synthetic non-hydrolyzable analog designed for oral bioavailability the parent Ang IV lacks.
Sold across the nootropic peptide community with cognitive-enhancement implications the primary literature has only preliminary support for. Harding's group's work is real and interesting. The gap between animal-model studies and injectable/oral consumer use is not bridged by any published clinical trial.
Straight talk
Straight talk: Dihexa has essentially zero human clinical trial data. The published record is Harding's WSU group and collaborators — cell-culture and rodent-model work on the c-Met/HGF pathway. It is a research chemical with an interesting mechanism story and no clinical evidence base whatsoever. Anyone marketing it as a cognitive enhancer is running years ahead of the science.
What the research studies
The literature, not a summary of it.
The founding work is Joseph Harding's group at Washington State University. Cross-reference angiotensin IV / IRAP receptor biology (Chai, Albiston, Wright). Journals: J Pharmacol Exp Ther, ACS Chem Neurosci, Behav Brain Res. Read the research yourself:
Recommended vendor · Amino Club
≥ 99% by HPLC on the current lot — ILS Laboratories (ISO/IEC 17025).
$38.99 during Fall Sale (was $59.99)
35% off applied automatically at checkout when you land through this link.